Eagle Pharmaceuticals Inc (EGRX) Position Decreased by BlackRock Inc.

BlackRock Inc. decreased its stake in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) by 0.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,731,054 shares of the specialty pharmaceutical company’s stock after selling 10,658 shares during the period. BlackRock Inc. owned approximately 11.61% of Eagle Pharmaceuticals worth $69,745,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in EGRX. Vanguard Group Inc. raised its holdings in shares of Eagle Pharmaceuticals by 9.7% in the third quarter. Vanguard Group Inc. now owns 674,951 shares of the specialty pharmaceutical company’s stock valued at $46,794,000 after buying an additional 59,474 shares during the last quarter. Vanguard Group Inc raised its holdings in shares of Eagle Pharmaceuticals by 9.7% in the third quarter. Vanguard Group Inc now owns 674,951 shares of the specialty pharmaceutical company’s stock valued at $46,794,000 after buying an additional 59,474 shares during the last quarter. WINTON GROUP Ltd bought a new position in shares of Eagle Pharmaceuticals in the fourth quarter valued at about $9,552,000. Chartwell Investment Partners LLC increased its position in Eagle Pharmaceuticals by 38.9% in the fourth quarter. Chartwell Investment Partners LLC now owns 216,187 shares of the specialty pharmaceutical company’s stock worth $8,710,000 after purchasing an additional 60,578 shares during the period. Finally, Bank of New York Mellon Corp increased its position in Eagle Pharmaceuticals by 15.6% in the third quarter. Bank of New York Mellon Corp now owns 177,619 shares of the specialty pharmaceutical company’s stock worth $12,314,000 after purchasing an additional 23,903 shares during the period. Institutional investors and hedge funds own 94.36% of the company’s stock.

In other Eagle Pharmaceuticals news, CEO Scott Tarriff sold 24,975 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $50.15, for a total value of $1,252,496.25. Following the sale, the chief executive officer now owns 1,500,202 shares in the company, valued at approximately $75,235,130.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 79,488 shares of company stock worth $3,752,208 in the last 90 days. Company insiders own 28.20% of the company’s stock.

EGRX has been the subject of a number of research reports. BidaskClub upgraded Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 23rd. ValuEngine lowered Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, April 9th. Royal Bank of Canada set a $66.00 target price on Eagle Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, March 1st. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a research report on Friday, February 1st. Finally, Mizuho restated a “hold” rating and set a $50.00 target price on shares of Eagle Pharmaceuticals in a research report on Wednesday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company. Eagle Pharmaceuticals has a consensus rating of “Hold” and an average price target of $65.17.

Shares of NASDAQ:EGRX traded down $0.32 during trading on Wednesday, hitting $51.72. 160,100 shares of the company’s stock traded hands, compared to its average volume of 200,204. The stock has a market capitalization of $675.87 million, a PE ratio of 24.76 and a beta of 1.72. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.13 and a quick ratio of 3.92. Eagle Pharmaceuticals Inc has a 52 week low of $36.03 and a 52 week high of $85.66.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its earnings results on Thursday, February 28th. The specialty pharmaceutical company reported $1.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.04. The firm had revenue of $56.05 million for the quarter, compared to analysts’ expectations of $54.17 million. Eagle Pharmaceuticals had a return on equity of 17.76% and a net margin of 14.96%. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.05 EPS. On average, research analysts expect that Eagle Pharmaceuticals Inc will post 2.69 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/24/blackrock-inc-sells-10658-shares-of-eagle-pharmaceuticals-inc-egrx.html.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

Further Reading: Market Capitalization and Individual Investors

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.